OM336 not checked
Lakefront Biotherapeutics West LLC
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “OM336 is an engineered bispecific antibody directed against BCMA and CD3”In the company’s words, NCT07083960 on ClinicalTrials.gov
- Tested for
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia, Sjogrens Disease, Idiopathic Inflammatory Myopathy (IIM)
- Main trialPhase 1
- “An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.”In the company’s words, NCT07083960 on ClinicalTrials.gov
Other drugs for AIHA - Cold Autoimmune Hemolytic Anemia
- RilzabrutinibSanofi · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 1/2
- BMS-986353Bristol Myers Squibb · Phase 2
- YTS109China Immunotech (Beijing) Biotechnology Co., Ltd. · Phase 1
- Arnovie101Circunited BioPharma · Early Phase 1
- HY001NJuventas Cell Therapy Ltd. · Phase 1
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2026 | OM336 in Autoimmune Cytopenias | |
| Phase 1Recruiting | Jun 2027 | OM336 in Seropositive Autoimmune Diseases | |
| Phase 2Authorised | not given | An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026